Puberty Menorrhagia is defined as excessive bleeding in amount (>80ml) or in duration (>7days) or both between menarche and 19 years of age. The SHD is a Unani formulation that has been claimed as a powerful haemostatic drug. The trial was a standard controlled randomized single blind study. The study was conducted on 55 unmarried girls aged between 12-19 yrs having regular cycle with heavy bleeding during menstruation at National Institute of Unani Medicine (NIUM) Hospital, Bangalore during the year of 2008-09. They were randomly allocated in test and control groups respectively and patients showed Pictorial Blood loss Assessment Chart (PBAC) score of more than 200 were included in the study. All the patients were given the treatment throughout menses period from 1st day till the bleeding stopped for three consecutive cycles. Evaluation of DOF was assessed by PBAC score in each cycle and the results were analyzed using appropriate statistical tests. There was significant reduction on DOF in both groups (p< 0.001) when compared with the mean score of PBAC before treatment. Mean reduction in PBAC score in SHD treated group was found to be more even than the standard drug (p< 0.001). The study demonstrated that the test drug SHD is effective in ameliorating the Puberty Menorrhagia. The study thus validated the claim of Unani medicine that the group of drugs possessing astringent and potent styptic activity may be used in arresting the Puberty Menorrhagia successfully.